What is the recommended acute and suppressive treatment for recurrent herpes labialis in a typical adult, including dosing and special considerations for pregnancy and immunocompromised patients?

Herpes Labialis Reactivation Treatment

Acute Episodic Treatment

For acute herpes labialis, initiate valacyclovir 2 g twice daily for 1 day (doses separated by 12 hours) at the first sign of prodromal symptoms or within 24 hours of lesion onset. 1

First-Line Oral Antiviral Options

• Valacyclovir 2 g twice daily for 1 day is the preferred first-line treatment, reducing median episode duration by 1.0 day compared to placebo 1
• Famciclovir 1500 mg as a single dose provides equivalent efficacy with the convenience of single-day dosing 1, 2
• Acyclovir 400 mg five times daily for 5 days remains effective but requires more frequent dosing and may reduce adherence 1, 3

Critical Timing Considerations

• Treatment must be initiated during the prodromal phase (tingling, burning, itching) or within 24 hours of lesion onset to achieve optimal benefit 1
• Peak viral titers occur in the first 24 hours after lesion appearance, making early intervention essential for blocking viral replication 1
• Patient-initiated therapy at first symptoms may prevent lesion development in some cases 1
• Efficacy decreases significantly when treatment starts after lesions have fully developed 1

Topical Therapy Limitations

• Topical antivirals (acyclovir cream, penciclovir cream) provide only modest clinical benefit and are substantially less effective than oral therapy 1, 3
• Topical agents cannot reach the site of viral reactivation in sensory ganglia and are not effective for prevention 1, 4

---

Chronic Suppressive Therapy

For patients with six or more recurrences per year, initiate daily suppressive therapy with valacyclovir 500 mg once daily, which reduces recurrence frequency by ≥75%. 1

Indications for Suppressive Therapy

• Six or more recurrences per year 1
• Particularly severe, frequent, or complicated disease 1
• Significant psychological distress from recurrences 1

Suppressive Regimen Options

• Valacyclovir 500 mg once daily (can increase to 1000 mg once daily for very frequent recurrences) 1
• Famciclovir 250 mg twice daily 1
• Acyclovir 400 mg twice daily 1

Duration and Monitoring

• Safety and efficacy documented for acyclovir up to 6 years of continuous use 1
• Valacyclovir and famciclovir have documented safety for 1 year of continuous use 1
• After 1 year of continuous suppressive therapy, consider discontinuation to reassess recurrence frequency, as it decreases over time in many patients 1
• Suppressive therapy reduces but does not eliminate asymptomatic viral shedding 1

---

Special Population Considerations

Immunocompromised Patients

• Episodes are typically longer and more severe, potentially involving the entire oral cavity or extending across the face 1, 4
• May require higher doses or longer treatment durations 1
• Acyclovir resistance rates are substantially higher (7% versus <0.5% in immunocompetent patients) 1
• For severe intraoral HSV or gingivostomatitis requiring hospitalization, use acyclovir 5-10 mg/kg IV every 8 hours until lesions begin to regress, then switch to oral therapy 1
• For mild symptomatic gingivostomatitis, use acyclovir 20 mg/kg (maximum 400 mg/dose) orally three times daily for 5-10 days 1

HIV-Infected Patients

• For recurrent orolabial herpes in HIV-infected patients, use famciclovir 500 mg twice daily for 7 days 2
• Higher doses or longer treatment durations may be required compared to immunocompetent hosts 1

Pregnancy Considerations

• The provided evidence does not contain specific dosing recommendations for pregnancy
• General antiviral safety profiles suggest acyclovir has the most extensive safety data in pregnancy, though specific herpes labialis dosing in pregnancy is not addressed in these guidelines

Renal Impairment

• Dose adjustments are mandatory for all oral antivirals based on creatinine clearance 1
• For famciclovir in herpes labialis with CrCl 40-59 mL/min: 750 mg single dose 2
• For famciclovir with CrCl 20-39 mL/min: 500 mg single dose 2
• For famciclovir with CrCl <20 mL/min: 250 mg single dose 2
• For hemodialysis patients: 250 mg following each dialysis 2

---

Acyclovir-Resistant HSV

• Resistance remains rare in immunocompetent hosts (<0.5%) despite increasing antiviral use 1
• For confirmed acyclovir-resistant HSV infection, use foscarnet 40 mg/kg IV three times daily 1
• All acyclovir-resistant strains are also resistant to valacyclovir, and most are resistant to famciclovir 1

---

Preventive Counseling

• Patients should identify and avoid personal triggers including ultraviolet light exposure, fever, psychological stress, and menstruation 1, 5
• Applying sunscreen (SPF ≥15) or zinc oxide to the lips can decrease the probability of UV light-triggered recurrences 1
• Patients remain contagious until all lesions are fully crusted 1
• Avoid direct contact (kissing) and sharing items that contact the mouth (towels, utensils, lip balm) during active outbreaks 1

---

Common Pitfalls to Avoid

• Relying solely on topical treatments when oral therapy is significantly more effective 1
• Starting treatment too late—efficacy decreases markedly after the first 24 hours 1
• Failing to consider suppressive therapy in patients with ≥6 recurrences per year who could benefit substantially 1
• Not discussing trigger avoidance (UV exposure, stress, fever) even while on suppressive therapy 1
• Using inadequate dosing—short-course, high-dose therapy is more effective than traditional longer courses 1